 SAN DIEGO, May 12, 2021 PRNewswire -- BioAtla, Inc. Nasdaq: BCAB, a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic CAB antibody therapeutics, today announced financial results for the first quarter of 2021 and provided an update on its business. BioAtla is rapidly advancing potentially registration-enabling Phase 2 clinical trials for our two lead CAB product candidates. 